- Trial phase
- Approved (FDA PMA P250036)
- Time to market
- Already on the market. The test received FDA 510(k) clearance as a tumor profiling test in April 2020, and received FDA PMA approval as a companion diagnostic for BRAF V600E/K in advanced melanoma on August 10, 2026. It is currently commercially available from Labcorp.
- Why 3/10
- This is an already-approved, commercialized in vitro diagnostic. No pending PDUFA date, pivotal readout, or regulatory decision is scheduled for this product in the next 12 months. For a large-cap company like Labcorp (~$12B+ annual revenue), this single test is a small part of a diversified diagnostics portfolio, so even a meaningful commercial outcome would not be a hard, dated catalyst for the stock.
PGDx elio tissue complete CDx is already FDA-approved and commercialized. No near-term binary catalyst exists for this specific product. For Labcorp investors, the relevant watchpoint is broader adoption trends in precision oncology diagnostics and how Labcorp's kitted solution competes against central-lab models from Foundation Medicine (Roche) and Guardant Health, but this single product is too small to drive LH shares materially. The stock's next scheduled catalyst is ongoing earnings execution across Labcorp's diagnostics and drug-development segments.
Price Chart
Executive Summary
PGDx elio tissue complete CDx is an FDA-approved companion diagnostic test developed by Labcorp (NYSE: LH) through its 2022 acquisition of Personal Genome Diagnostics. The test uses next-generation sequencing to analyze 505 cancer-related genes from tumor tissue and is specifically approved as a companion diagnostic to identify BRAF V600E/V600K mutations in advanced melanoma, guiding use of BRAF and BRAF/MEK inhibitor therapies. It was originally cleared by the FDA via 510(k) in April 2020 as a tumor profiling test and received PMA approval as a CDx on August 10, 2026. The test is marketed as the first and only FDA-cleared tumor profiling kitted solution, designed for use in hospital and clinical laboratories rather than requiring send-out to central reference labs. For Labcorp, this is a commercial-stage product within a much larger diagnostics and life sciences business, and no upcoming binary regulatory catalyst exists.
How It Works
PGDx elio tissue complete CDx is a laboratory test that uses next-generation DNA sequencing to analyze a tumor tissue sample. It reads the DNA across 505 cancer-related genes to find mutations that can guide treatment decisions. Specifically, the test is FDA-approved as a companion diagnostic to detect BRAF V600E and V600K mutations in advanced melanoma tumors, identifying patients who may respond to BRAF inhibitor or BRAF/MEK inhibitor targeted therapies. It also provides broader tumor genomic profiling information beyond its companion diagnostic claim.
Trial Status
The test achieved FDA PMA approval (P250036) on August 10, 2026, as a companion diagnostic for BRAF V600E/V600K in advanced melanoma. This followed an earlier 510(k) clearance (K192063) in April 2020 for general tumor mutation profiling. The PMA approval was supported by clinical validation demonstrating non-inferiority to existing FDA-approved companion diagnostics.
The Two-Sided Case
Upcoming Catalysts
- No near-term binary catalyst for this specific product. Future catalysts could include FDA clearance of additional companion diagnostic claims for other drugs/tumor types using the same test platform, but none are currently announced or scheduled.
Source Filing
The SecBot filing or press-release report that triggered this drug report:
LABCORP HOLDINGS INC. 8-K LH ·Originating report